Clinical Trial Update: Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating lapatinib in patients with relapsed esophageal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Adenocarcinoma | Phase 2 | Status: COMPLETED